Radioembolization of liver tumors with yttrium-90 microspheres

H Ahmadzadehfar, HJ Biersack, S Ezziddin - Seminars in nuclear medicine, 2010 - Elsevier
Radioembolization (RE), also termed selective internal radiation therapy (SIRT), has been
gradually introduced to the clinical arsenal of cytoreductive modalities in recent years. There …

[HTML][HTML] HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and …

…, A Vogg, NCL Wong, HH Ting, HJ Biersack… - European journal of …, 2021 - Springer
Purpose The aim of the present paper is to review the role of HER2 antibodies, affibodies and
nanobodies as vehicles for imaging and therapy approaches in breast cancer, including a …

Theranostic approach in breast cancer: a treasured tailor for future oncology

…, E Jafari, HH Ting, HJ Biersack… - Clinical Nuclear …, 2021 - journals.lww.com
Breast cancer is the most frequent invasive malignancy and the second major cause of
cancer death in female subjects mostly due to the considerable diagnostic delay and failure of …

Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study

…, G Hiltermann, U Cremerius, HJ Biersack - European journal of …, 1999 - Springer
Original article Page 1 Abstract. The aim of this multicentre study was to evaluate the clinical
significance of fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) …

Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours

…, K Mayer, A Al Zreiqat, W Willinek, HJ Biersack… - European journal of …, 2014 - Springer
Purpose The clinical benefit of peptide receptor radionuclide therapy (PRRT) in patients with
pancreatic neuroendocrine tumours (pNET) has not yet been well described and defined in …

Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with …

…, F Grünwald, S Guhlke, HJ Biersack… - Journal of nuclear …, 2014 - Soc Nuclear Med
Outcome analyses for patients with gastroenteropancreatic neuroendocrine tumors (GEP NET)
after peptide receptor radionuclide therapy (PRRT) are still limited, especially with regard …

Dose escalation study with rhenium-188 hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastases

…, J Risse, F Grünwald, FF Knapp Jr, HJ Biersack - European journal of …, 2000 - Springer
Original article Page 1 Abstract. The aim of this study was to determine the maximum
tolerated dose of rhenium-188 hydroxyethylidene diphosphonate (HEDP) in prostate cancer …

Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: randomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 …

…, FF Knapp Jr, S Guhlke, HJ Biersack - Journal of clinical …, 2003 - ascopubs.org
Purpose: We investigated the effect of repeated bone-targeted therapy with rhenium-188
hydroxyethylidenediphosphonate (HEDP) in patients with progressive, hormone-resistant …

Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate

…, T Pöppel, S Guhlke, HJ Biersack… - Journal of Nuclear …, 2013 - Soc Nuclear Med
Myelosuppression may be the dose-limiting toxicity in peptide receptor radionuclide therapy
(PRRT). The aim of this study was to investigate the incidence, severity, and reversibility of …

The significance of 99mTc-MAA SPECT/CT liver perfusion imaging in treatment planning for 90Y-microsphere selective internal radiation treatment

…, C Kuhl, K Wilhelm, HJ Biersack… - Journal of Nuclear …, 2010 - Soc Nuclear Med
Selective internal radiation therapy (SIRT), a catheter-based liver-directed modality for
treating primary and metastatic liver cancer, requires appropriate planning to maximize its …